Poster
Quizartinib
HOPA 2025 | April 9-12, 2025
Hematology
QuANTUM-First: Effects of quizartinib on RFS, OS, CIR, and MRD in newly diagnosed patients with FMS-like tyrosine kinase 3-internal tandem duplication–positive acute myeloid leukemia who received maintenance therapy
Mark J. Levis
Poster
Quizartinib
HOPA 2025 | April 9-12, 2025
Hematology
QuANTUM-First: Safety by treatment phase and by age in newly diagnosed patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) positive acute myeloid leukemia
Harry P. Erba
Poster
Quizartinib
HOPA 2025 | April 9-12, 2025
Hematology
Trial in progress: The phase 3, randomized, double-blind, placebo-controlled QuANTUM-Wild study of quizartinib in combination with chemotherapy and as single-agent maintenance in newly diagnosed, FLT3-ITD–negative acute myeloid leukemia
Pau Montesinos